Mazen S. Bader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mazen S. Bader has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Annie Brooks
Clinical Pharmacist, Infectious Diseases and Antimicrobial Stewardship, Hamilton Health Services, Juravinski Hospital, Hamilton, Ontario, Canada
3 shared publicationsJohn Hawboldt
3 shared publicationsMd
3 shared publicationsDeborah V. Kelly
School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada
2 shared publications- Jocelyn A. Srigley
Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia
2 shared publications - John Hawboldt
School of Pharmacy, Memorial University, St. John's, Newfoundland and Labrador, Canada
2 shared publications
Latest Publications
- 1 January 2017
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 84 (1) , 65-80
Postexposure management of infectious diseases
Release date: January 1, 2017Expiration date: December 31, 2017Estimated time of completion: 1 hourClick here to start this CME activity.Click here to complete post-test and CME certificate.ABSTRACTAnyone exposed to an infectious disease—whether a healthcare provider, patient, or contact of a patient—should be evaluated promptly and the source of the infection identified. A systematic response entails postexposure prophylactic therapy if available and indicated, infection control measures to prevent further transmission, counseling and educating those involved, and assessing those who may require work restriction or modification.
- 1 January 2017
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 84 (1) , 65-80
Postexposure management of infectious diseases
Release date: January 1, 2017Expiration date: December 31, 2017Estimated time of completion: 1 hourClick here to start this CME activity.Click here to complete post-test and CME certificate.ABSTRACTAnyone exposed to an infectious disease—whether a healthcare provider, patient, or contact of a patient—should be evaluated promptly and the source of the infection identified. A systematic response entails postexposure prophylactic therapy if available and indicated, infection control measures to prevent further transmission, counseling and educating those involved, and assessing those who may require work restriction or modification.
- 1 January 2017
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 25 (1) , 29-32
Prevalence and Clinical Characteristics of Gastroesophageal Reflux Disease in Human Immunodeficiency Virus–Infected Adults
Gastroesophageal reflux disease (GERD) is common in the general population, but its burden is unknown in human immunodeficiency virus (HIV)–infected adults. The primary objective of the study was to determine the prevalence and clinical characteristics of GERD in HIV-infected adults. We conducted a cross-sectional study of 85 HIV-infected adults from 2 HIV clinics in Canada. The patients completed a validated GERD questionnaire during their scheduled clinic visits. Eighty-five HIV-infected adults were included in the analysis. Mean age, median body mass index, and median waist circumference were 44 years, 25 cm, and 93 cm, respectively. Sixty-eight patients (81%) had GERD, and 52 (77%) of them were male. Of the 68 adults with GERD, 36 (52.9%) were classified as frequent, and 42 (61.8%) were classified as moderate-severe. Twenty-two patients had metabolic syndrome, of whom 19 (86.4%) had GERD symptoms. The weight of patients with GERD was higher than that in patients without GERD (75 [interquartile range, 19.5] and 63.35 [interquartile range, 19.8] kg, respectively; P = 0.04). Sixty-five patients (95.6%) who had GERD symptoms were taking medications to treat it. Most patients (92.3%) were on histamine-2 receptor antagonists. Gastroesophageal reflux disease is prevalent among HIV-infected adults, and more than half of the patients present with symptoms described as frequent and/or moderate-severe in intensity. The screening and management of GERD are important considerations as part of routine HIV care.
- 1 January 2017
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 25 (1) , 29-32
Prevalence and Clinical Characteristics of Gastroesophageal Reflux Disease in Human Immunodeficiency Virus–Infected Adults
Gastroesophageal reflux disease (GERD) is common in the general population, but its burden is unknown in human immunodeficiency virus (HIV)–infected adults. The primary objective of the study was to determine the prevalence and clinical characteristics of GERD in HIV-infected adults. We conducted a cross-sectional study of 85 HIV-infected adults from 2 HIV clinics in Canada. The patients completed a validated GERD questionnaire during their scheduled clinic visits. Eighty-five HIV-infected adults were included in the analysis. Mean age, median body mass index, and median waist circumference were 44 years, 25 cm, and 93 cm, respectively. Sixty-eight patients (81%) had GERD, and 52 (77%) of them were male. Of the 68 adults with GERD, 36 (52.9%) were classified as frequent, and 42 (61.8%) were classified as moderate-severe. Twenty-two patients had metabolic syndrome, of whom 19 (86.4%) had GERD symptoms. The weight of patients with GERD was higher than that in patients without GERD (75 [interquartile range, 19.5] and 63.35 [interquartile range, 19.8] kg, respectively; P = 0.04). Sixty-five patients (95.6%) who had GERD symptoms were taking medications to treat it. Most patients (92.3%) were on histamine-2 receptor antagonists. Gastroesophageal reflux disease is prevalent among HIV-infected adults, and more than half of the patients present with symptoms described as frequent and/or moderate-severe in intensity. The screening and management of GERD are important considerations as part of routine HIV care.
- Open Access
- 30 September 2015
- Published by ClinMed International Library in International Journal of Respiratory and Pulmonary Medicine
- Vol. 2 (3)
Outcomes of Moderate-Severe Community-Acquired Pneumonia in Patients with Diabetes Mellitus: Impact of Systemic Steroids and Time to First Dose of Appropriate Antibiotic Therapy
In patients with diabetes mellitus (DM), community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. The primary objective of the study was to describe the clinical outcomes and risk factors for moderate-severe CAP in hospitalized patients with DM.
- 30 September 2015
- Published by ClinMed International Library in International Journal of Respiratory and Pulmonary Medicine
- Vol. 2 (3)
Open AccessOutcomes of Moderate-Severe Community-Acquired Pneumonia in Patients with Diabetes Mellitus: Impact of Systemic Steroids and Time to First Dose of Appropriate Antibiotic Therapy
In patients with diabetes mellitus (DM), community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. The primary objective of the study was to describe the clinical outcomes and risk factors for moderate-severe CAP in hospitalized patients with DM.
- 1 March 2015
- Published by Taylor & Francis in Hospital Practice
- Vol. 43 (2) , 107-127
Postexposure management of healthcare personnel to infectious diseases
Healthcare personnel (HCP) are at risk of exposure to various pathogens through their daily tasks and may serve as a reservoir for ongoing disease transmission in the healthcare setting. Management of HCP exposed to infectious agents can be disruptive to patient care, time-consuming, and costly. Exposure of HCP to an infectious source should be considered an urgent medical concern to ensure timely management and administration of postexposure prophylaxis, if available and indicated. Infection control and occupational health departments should be notified for management of exposed HCP, identification of all contacts of the index case, and application of immediate infection control measures for the index case and exposed HCP, if indicated. This article reviews the main principles of postexposure management of HCP to infectious diseases, in general, and to certain common infections, in particular, categorized by their route of transmission, in addition to primary prevention of these infections.
- 1 March 2015
- Published by Taylor & Francis in Hospital Practice
- Vol. 43 (2) , 107-127
Postexposure management of healthcare personnel to infectious diseases
Healthcare personnel (HCP) are at risk of exposure to various pathogens through their daily tasks and may serve as a reservoir for ongoing disease transmission in the healthcare setting. Management of HCP exposed to infectious agents can be disruptive to patient care, time-consuming, and costly. Exposure of HCP to an infectious source should be considered an urgent medical concern to ensure timely management and administration of postexposure prophylaxis, if available and indicated. Infection control and occupational health departments should be notified for management of exposed HCP, identification of all contacts of the index case, and application of immediate infection control measures for the index case and exposed HCP, if indicated. This article reviews the main principles of postexposure management of HCP to infectious diseases, in general, and to certain common infections, in particular, categorized by their route of transmission, in addition to primary prevention of these infections.
- 1 October 2014
- Published by Taylor & Francis in Hospital Practice
- Vol. 42 (4) , 111-125
Management of Hospitalized Patients with Diabetic Foot Infections
Diabetic foot infections (DFIs), which present with a variety of clinical manifestations, are commonly encountered by clinicians. They are associated with a high morbidity, a high amputation rate, a high mortality, and increased health care costs. An effective management of DFIs requires a multidisciplinary approach with a strong collaboration among all involved health care providers as well as patient involvement. Diagnosing DFIs appropriately requires consideration of the clinical symptoms and signs of infection in addition to supplementary laboratory testing such as inflammatory markers and imaging studies. The comprehensive patient assessment should include the predisposing risk factors for infection; the type, severity, and extent of the infection; and the assessment of neurologic and vascular status, comorbid conditions, and psychosocial factors. The comprehensive management of DFIs include not only effective antibiotic therapy but also surgical debridement, pressure offloading, wound care and moisture, maintaining good vascular perfusion, control of edema and pain, correction of metabolic abnormalities such as hyperglycemia, and addressing psychosocial and nutritional issues. Discharge planning that addresses full medical and social needs along with suitable follow-up, patient education and counseling, and clear communication with outpatient providers are critical for ensuring a safe and successful transition to outpatient management of hospitalized patients with DFIs.
- 1 October 2014
- Published by Taylor & Francis in Hospital Practice
- Vol. 42 (4) , 111-125
Management of Hospitalized Patients with Diabetic Foot Infections
Diabetic foot infections (DFIs), which present with a variety of clinical manifestations, are commonly encountered by clinicians. They are associated with a high morbidity, a high amputation rate, a high mortality, and increased health care costs. An effective management of DFIs requires a multidisciplinary approach with a strong collaboration among all involved health care providers as well as patient involvement. Diagnosing DFIs appropriately requires consideration of the clinical symptoms and signs of infection in addition to supplementary laboratory testing such as inflammatory markers and imaging studies. The comprehensive patient assessment should include the predisposing risk factors for infection; the type, severity, and extent of the infection; and the assessment of neurologic and vascular status, comorbid conditions, and psychosocial factors. The comprehensive management of DFIs include not only effective antibiotic therapy but also surgical debridement, pressure offloading, wound care and moisture, maintaining good vascular perfusion, control of edema and pain, correction of metabolic abnormalities such as hyperglycemia, and addressing psychosocial and nutritional issues. Discharge planning that addresses full medical and social needs along with suitable follow-up, patient education and counseling, and clear communication with outpatient providers are critical for ensuring a safe and successful transition to outpatient management of hospitalized patients with DFIs.
- 1 September 2013
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 125 (5) , 78-91
Herpes Zoster: Diagnostic, Therapeutic, and Preventive Approaches
Herpes zoster (Hz), which generally presents as a localized, painful cutaneous eruption, is a common clinical problem, particularly among adults ≥ 50 years of age and immunocompromised patients. The diagnosis of Hz is mainly made clinically, except in patients with atypical manifestations or certain complications, such as central nervous system involvement, in which laboratory virologic testing is required. In addition to having a higher mortality rate, immunocompromised individuals have atypical and severe clinical findings and are at greater risk for complications and recurrence of Hz. Treatment of Hz includes the use of antiviral agents, analgesics for control of acute zoster pain, good skin care for healing, and prevention of secondary bacterial infection. Antiviral agents, preferably valacyclovir or famciclovir, should be started within 72 hours of onset to reduce the severity of the infection, the duration of the eruptive phase, and the intensity of acute pain. Herpes zoster has been associated with several complications, of which post-herpetic neuralgia (PHN) is the most common and debilitating. Varicella-zoster virus vaccine and early treatment with either famciclovir or valacyclovir are the only measures proven to prevent PHN. The options for treating PHN include topical agents, such as lidocaine patches, and systemic agents, such as the anticonvulsants gabapentin and pregabalin. Measures for preventing Hz include infection control through routine hand hygiene and appropriate use of isolation precautions and personal protective equipment; immunoglobulins, such as the varicella-zoster virus immunoglobulin and vaccine; and antiviral agents. The zoster vaccine has been shown to be effective in reducing the incidence of Hz and PHN. The vaccine is recommended for all individuals aged ≥ 60 years who have no contraindications, including individuals who report a previous episode of Hz.
- 1 September 2013
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 125 (5) , 78-91
Herpes Zoster: Diagnostic, Therapeutic, and Preventive Approaches
Herpes zoster (Hz), which generally presents as a localized, painful cutaneous eruption, is a common clinical problem, particularly among adults ≥ 50 years of age and immunocompromised patients. The diagnosis of Hz is mainly made clinically, except in patients with atypical manifestations or certain complications, such as central nervous system involvement, in which laboratory virologic testing is required. In addition to having a higher mortality rate, immunocompromised individuals have atypical and severe clinical findings and are at greater risk for complications and recurrence of Hz. Treatment of Hz includes the use of antiviral agents, analgesics for control of acute zoster pain, good skin care for healing, and prevention of secondary bacterial infection. Antiviral agents, preferably valacyclovir or famciclovir, should be started within 72 hours of onset to reduce the severity of the infection, the duration of the eruptive phase, and the intensity of acute pain. Herpes zoster has been associated with several complications, of which post-herpetic neuralgia (PHN) is the most common and debilitating. Varicella-zoster virus vaccine and early treatment with either famciclovir or valacyclovir are the only measures proven to prevent PHN. The options for treating PHN include topical agents, such as lidocaine patches, and systemic agents, such as the anticonvulsants gabapentin and pregabalin. Measures for preventing Hz include infection control through routine hand hygiene and appropriate use of isolation precautions and personal protective equipment; immunoglobulins, such as the varicella-zoster virus immunoglobulin and vaccine; and antiviral agents. The zoster vaccine has been shown to be effective in reducing the incidence of Hz and PHN. The vaccine is recommended for all individuals aged ≥ 60 years who have no contraindications, including individuals who report a previous episode of Hz.
- 1 July 2013
- Vol. 88 (1) , 25-32
Postexposure prophylaxis for common infectious diseases.
Postexposure prophylaxis (PEP) is effective in preventing illness after potential or documented exposure to a variety of microbial pathogens and in reducing the risk of secondary spread of infection. Guidelines have been published by the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices for proper use of PEP for bloodborne pathogens, for microorganisms transmitted by either airborne or droplet spread or through direct contact, and for infections acquired after traumatic injuries. Depending on the type of exposure, different forms of PEP are available, including vaccines, immune globulins, antibiotics, and antiviral medications. Physicians should assess a patient's potential need for PEP based on several factors, including the type of exposure, the timing and severity of illness in the source patient, the exposed person's susceptibility to infectious diseases of concern, and the relative risks and benefits of the PEP regimen in an individual situation. Immunity to certain infectious diseases can be ensured with prior infection or vaccination, and by serologic testing in patients with a negative or uncertain history. PEP should be given to persons exposed to index cases of pertussis and invasive meningococcal infection regardless of immunization history, and should be given following rabies and tetanus exposure regardless of the length of delay. In general, PEP should be given as soon as possible following a high-risk exposure. Persons exposed to bloodborne pathogens should have baseline testing for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus antibodies, and follow-up testing at six weeks, three months, and six months postexposure.
- 1 July 2013
- Vol. 88 (1) , 25-32
Postexposure prophylaxis for common infectious diseases.
Postexposure prophylaxis (PEP) is effective in preventing illness after potential or documented exposure to a variety of microbial pathogens and in reducing the risk of secondary spread of infection. Guidelines have been published by the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices for proper use of PEP for bloodborne pathogens, for microorganisms transmitted by either airborne or droplet spread or through direct contact, and for infections acquired after traumatic injuries. Depending on the type of exposure, different forms of PEP are available, including vaccines, immune globulins, antibiotics, and antiviral medications. Physicians should assess a patient's potential need for PEP based on several factors, including the type of exposure, the timing and severity of illness in the source patient, the exposed person's susceptibility to infectious diseases of concern, and the relative risks and benefits of the PEP regimen in an individual situation. Immunity to certain infectious diseases can be ensured with prior infection or vaccination, and by serologic testing in patients with a negative or uncertain history. PEP should be given to persons exposed to index cases of pertussis and invasive meningococcal infection regardless of immunization history, and should be given following rabies and tetanus exposure regardless of the length of delay. In general, PEP should be given as soon as possible following a high-risk exposure. Persons exposed to bloodborne pathogens should have baseline testing for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus antibodies, and follow-up testing at six weeks, three months, and six months postexposure.
- 13 March 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (2) , 102-113
Medical Management of Diabetic Foot Infections
Diabetic foot infections (DFIs) are a commonly encountered medical problem. They are associated with an increased frequency and length of hospitalization and risk for lower–extremity amputation. Furthermore, they have substantial economic consequences. Patients with diabetes mellitus are particularly susceptible to foot infections because of neuropathy, vascular insufficiency, and diminished neutrophil function. The approach to managing DFIs starts with determining if an infection exists. If an infection exists, then the type, severity, extent of infection, and risk factors for resistant organisms should be determined through history, physical examination, and additional laboratory and radiological testing. Optimal management requires surgical debridement, pressure offloading, effective antibiotic therapy, wound care and moisture, maintaining good vascular supply, and correction of metabolic abnormalities, such as hyperglycemia, through a multidisciplinary team. Empiric antibiotics for DFIs vary b...
- 13 March 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (2) , 102-113
Medical Management of Diabetic Foot Infections
Diabetic foot infections (DFIs) are a commonly encountered medical problem. They are associated with an increased frequency and length of hospitalization and risk for lower–extremity amputation. Furthermore, they have substantial economic consequences. Patients with diabetes mellitus are particularly susceptible to foot infections because of neuropathy, vascular insufficiency, and diminished neutrophil function. The approach to managing DFIs starts with determining if an infection exists. If an infection exists, then the type, severity, extent of infection, and risk factors for resistant organisms should be determined through history, physical examination, and additional laboratory and radiological testing. Optimal management requires surgical debridement, pressure offloading, effective antibiotic therapy, wound care and moisture, maintaining good vascular supply, and correction of metabolic abnormalities, such as hyperglycemia, through a multidisciplinary team. Empiric antibiotics for DFIs vary b...
- 1 December 2011
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 104 (12) , 789-793
Risk Factors of Cellulitis Treatment Failure with Once-Daily Intravenous Cefazolin Plus Oral Probenecid
Objectives: Once-daily intravenous cefazolin with probenecid is used commonly to treat cellulitis. The primary objective of this study was to determine the risk factors of treatment failure with this regimen. Methods: This was a retrospective cohort study of adult outpatients with cellulitis who were initially treated with once-daily intravenous cefazolin plus probenecid. Treatment failure is...
- 1 December 2011
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 104 (12) , 789-793
Risk Factors of Cellulitis Treatment Failure with Once-Daily Intravenous Cefazolin Plus Oral Probenecid
Objectives: Once-daily intravenous cefazolin with probenecid is used commonly to treat cellulitis. The primary objective of this study was to determine the risk factors of treatment failure with this regimen. Methods: This was a retrospective cohort study of adult outpatients with cellulitis who were initially treated with once-daily intravenous cefazolin plus probenecid. Treatment failure is...
- 1 July 2011
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (4) , 284-285
Disseminated Intravascular Coagulation and Venous Thromboembolism Due to Acute Epstein-Barr Virus Infection
We describe a case of a healthy 61-year-old man who developed disseminated intravascular coagulation and venous thromboembolism secondary to acute Epstein-Barr virus (EBV) infection. The EBV was confirmed via serology and polymerase chain reaction. Although more common in children and young adults, acute EBV infection may also occur in middle-age and older adults and should be considered as a differential diagnosis in every patient presenting with disseminated intravascular coagulation.
- 1 July 2011
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (4) , 284-285
Disseminated Intravascular Coagulation and Venous Thromboembolism Due to Acute Epstein-Barr Virus Infection
We describe a case of a healthy 61-year-old man who developed disseminated intravascular coagulation and venous thromboembolism secondary to acute Epstein-Barr virus (EBV) infection. The EBV was confirmed via serology and polymerase chain reaction. Although more common in children and young adults, acute EBV infection may also occur in middle-age and older adults and should be considered as a differential diagnosis in every patient presenting with disseminated intravascular coagulation.